ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis.

Recent Posts

Have Any Questions?

Contact Us


Share This :